If you are hunting some new additions to your portfolio in June, then the ASX 200 stocks listed below could be worth a look.
They have both been named as favoured shares by Bell Potter for the month ahead. The broker notes that these are the shares that it believes "offer attractive risk-adjusted returns over the long term."
In addition, Bell Potter highlights that when choosing its picks it considers the current macro-economic backdrop and investment environment, focusing on quality companies with proven track records, capable management, and competitive advantages.
You can read about the first three ASX 200 stocks on the list here. Let's now take a look at two more of the broker's top picks:
Image source: Getty Images
Regis Resources Ltd (ASX: RRL)
This gold miner could be one of the best ASX 200 stocks to buy this month according to Bell Potter.
Regis Resources is a multi-mine gold producer with all its operating mines located in Western Australia. Its flagship project is the Duketon Gold Project and produces ~300k ounces per annum.
Bell Potter believes these assets are very attractive and could make the miner a takeover target in the future. It commented:
As one of the largest ASX listed gold producers, we are attracted to its all-Australian asset portfolio and organic growth options which are unique at this scale. Furthermore, we see key opportunities in the fundamental, medium-term outlook and, in our view, these may also make RRL an appealing corporate target in the current conducive M&A environment.
The broker has a buy rating and $2.80 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 stock that could be a best buy this month is ResMed.
It is a medical device company specialising in the obstructive sleep apnoea (OSA) market.
Bell Potter notes that this is a lucrative market to be in, with the OSA market growing in the high-single digits. And as ResMed is the largest player in the field, it stands to benefit greatly from its growth. It commented:
The market for OSA and chronic obstructive pulmonary disease (COPD) remains under penetrated, and we expect industry volume growth to continue in the 6-8% range for the foreseeable future. In this regard, the competitive dynamics are very much in favour of RMD due to the Philips recall and improving semiconductor availability. Furthermore, ResMed is well-positioned to build on its dominant share even after Philips returns to the global market, with the launch of its latest continuous positive airway pressure (CPAP) device, the Air Sense 11.
The broker has a buy rating and $36.00 price target on the ASX 200 stock.
